Core Laboratories N.V. (CLB) : Whv Investments reduced its stake in Core Laboratories N.V. by 94.26% during the most recent quarter end. The investment management company now holds a total of 30,329 shares of Core Laboratories N.V. which is valued at $3.5 Million after selling 498,169 shares in Core Laboratories N.V. , the firm said in a disclosure report filed with the SEC on May 11, 2016.Core Laboratories N.V. makes up approximately 1.94% of Whv Investments’s portfolio.
Other Hedge Funds, Including , Gsa Capital Partners Llp sold out all of its stake in CLB during the most recent quarter. The investment firm sold 13,574 shares of CLB which is valued $1.6 Million.Blackrock Japan Ltd reduced its stake in CLB by selling 79 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 58,681 shares of CLB which is valued at $6.9 Million. Core Laboratories N.V. makes up approx 0.03% of Blackrock Japan Ltd’s portfolio.Manufacturers Life Insurance Company The boosted its stake in CLB in the latest quarter, The investment management firm added 32 additional shares and now holds a total of 276 shares of Core Laboratories N.V. which is valued at $32,289.Mar Vista Investment Partners reduced its stake in CLB by selling 23,397 shares or 10.66% in the most recent quarter. The Hedge Fund company now holds 196,003 shares of CLB which is valued at $24.5 Million. Core Laboratories N.V. makes up approx 1.51% of Mar Vista Investment Partners’s portfolio.Underhill Investment Management reduced its stake in CLB by selling 34,625 shares or 26.76% in the most recent quarter. The Hedge Fund company now holds 94,780 shares of CLB which is valued at $12.7 Million. Core Laboratories N.V. makes up approx 6.47% of Underhill Investment Management’s portfolio.
Core Laboratories N.V. opened for trading at $119.05 and hit $119.16 on the upside on Monday, eventually ending the session at $117.46, with a gain of 0.40% or 0.47 points. The heightened volatility saw the trading volume jump to 6,87,266 shares. Company has a market cap of $4,980 M.
On the company’s financial health, Core Laboratories N.V. reported $0.37 EPS for the quarter, based on the information available during the earnings call on Apr 20, 2016. Analyst had a consensus estimate of $0.37. The company had revenue of $153.65 million for the quarter, compared to analysts expectations of $156.67 million. The company’s revenue was down -28.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.86 EPS.
Many Wall Street Analysts have commented on Core Laboratories N.V.. Company shares were Reiterated by Cowen on Apr 22, 2016 to “Market Perform”, Firm has raised the Price Target to $ 105 from a previous price target of $80 .Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Outperform”, Firm has raised the Price Target to $ 137 from a previous price target of $128 .Core Laboratories N.V. was Initiated by Citigroup to “Neutral” on Feb 29, 2016.
Core Laboratories N.V. (Core Lab) is a provider of proprietary and patented reservoir description production enhancement and reservoir management services to the oil and gas industry. These services and products are directed toward enabling its clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company operates in three segments: Reservoir Description Production Enhancement and Reservoir Management. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.